The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
What Happened: The FTC is disputing “junk patent listings” for diabetes, weight loss, asthma and COPD drugs. This initiative represents the latest endeavor against what the agency perceives as ...
FTC targets 300 Big Pharma 'junk patents,' sends warning letters to top drugmakers The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book ...
The Federal Trade Commission (FTC) continues slicing a machete through the patent thicket. On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds ...
Over the last eight months, the US Federal Trade Commission (FTC) has focused on what it characterizes as “improper” Orange Book listings and the impacts of such listings on generic entry.
Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...